The Argonaute Family: Tentacles That Reach Into Rnai, Developmental Control, Stem Cell Maintenance, and Tumorigenesis
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Not Dicer but Argonaute Is Required for a Microrna Production
Cell Research (2010) 20:735-737. npg © 2010 IBCB, SIBS, CAS All rights reserved 1001-0602/10 $ 32.00 RESEARCH HIGHLIGHT www.nature.com/cr A new twist in the microRNA pathway: Not Dicer but Argonaute is required for a microRNA production Gabriel D Bossé1, Martin J Simard1 1Laval University Cancer Research Centre, Hôtel-Dieu de Québec (CHUQ), Quebec City, Québec G1R 2J6, Canada Cell Research (2010) 20:735-737. doi:10.1038/cr.2010.83; published online 15 June 2010 Found in all metazoans, microRNAs A Canonical pathway B Ago2-dependent pathway or miRNAs are small non-coding RNA Nucleus Cytoplasm Nucleus Cytoplasm of ~22 nucleotides in length that com- Exp.5 Exp.5 pletely reshaped our understanding of gene regulation. This new class of gene pre-miR-451 regulator is mostly transcribed by the pre-miRNA RNA polymerase II producing a long stem-loop structure, called primary- or Ago2 pri-miRNA, that will first be processed Ago2 Dicer in the cell nucleus by a multiprotein TRBP complex called microprocessor to gen- erate a shorter RNA structure called Ago2 RISC precursor- or pre-miRNA. The precisely Ago2 RISC processed pre-miRNA will next be ex- ported into the cytoplasm by Exportin 5 and loaded onto another processing machine containing the ribonuclease III enzyme Dicer, an Argonaute protein Ago2 Ago2 and other accessory cellular factors mRNA mRNA (Figure 1A; [1]). Dicer will mediate the Translation inhibition Translation inhibition cleavage of the pre-miRNA to form the mature miRNA that will then be bound Figure 1 (A) Canonical microRNA biogenesis. In mammals, the pre-miRNA is by the Argonaute protein to form, most loaded onto a multiprotein complex consisting minimally of Dicer, Tar RNA Bind- likely with other cellular factors, the ef- ing Protein (TRBP) and Ago2. -
Anti-EIF2C1 / AGO1 Antibody (ARG63916)
Product datasheet [email protected] ARG63916 Package: 100 μg anti-EIF2C1 / AGO1 antibody Store at: -20°C Summary Product Description Goat Polyclonal antibody recognizes EIF2C1 / AGO1 Tested Reactivity Hu Predict Reactivity Ms, Rat, Dog Tested Application IHC-P, WB Specificity This product is not expected to cross-react with EIF2C2, EIF2C3 and EIF2C4. Host Goat Clonality Polyclonal Isotype IgG Target Name EIF2C1 / AGO1 Antigen Species Human Immunogen C-KNASYNLDPYIQEF Conjugation Un-conjugated Alternate Names GERP95; Q99; eIF2C 1; EIF2C; EIF2C1; Argonaute RISC catalytic component 1; Argonaute1; Protein argonaute-1; hAgo1; Putative RNA-binding protein Q99; eIF-2C 1; Eukaryotic translation initiation factor 2C 1 Application Instructions Application table Application Dilution IHC-P 2.5 µg/ml WB 0.3 - 1 µg/ml Application Note WB: Recommend incubate at RT for 1h. IHC-P: Antigen Retrieval: Steam tissue section in Citrate buffer (pH 6.0). * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 97 kDa Properties Form Liquid Purification Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. Buffer Tris saline (pH 7.3), 0.02% Sodium azide and 0.5% BSA Preservative 0.02% Sodium azide Stabilizer 0.5% BSA www.arigobio.com 1/3 Concentration 0.5 mg/ml Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. -
Gene Expression During Normal and FSHD Myogenesis Tsumagari Et Al
Gene expression during normal and FSHD myogenesis Tsumagari et al. Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 (27 September 2011) Tsumagari et al. BMC Medical Genomics 2011, 4:67 http://www.biomedcentral.com/1755-8794/4/67 RESEARCHARTICLE Open Access Gene expression during normal and FSHD myogenesis Koji Tsumagari1, Shao-Chi Chang1, Michelle Lacey2,3, Carl Baribault2,3, Sridar V Chittur4, Janet Sowden5, Rabi Tawil5, Gregory E Crawford6 and Melanie Ehrlich1,3* Abstract Background: Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disease linked to contraction of an array of tandem 3.3-kb repeats (D4Z4) at 4q35. Within each repeat unit is a gene, DUX4, that can encode a protein containing two homeodomains. A DUX4 transcript derived from the last repeat unit in a contracted array is associated with pathogenesis but it is unclear how. Methods: Using exon-based microarrays, the expression profiles of myogenic precursor cells were determined. Both undifferentiated myoblasts and myoblasts differentiated to myotubes derived from FSHD patients and controls were studied after immunocytochemical verification of the quality of the cultures. To further our understanding of FSHD and normal myogenesis, the expression profiles obtained were compared to those of 19 non-muscle cell types analyzed by identical methods. Results: Many of the ~17,000 examined genes were differentially expressed (> 2-fold, p < 0.01) in control myoblasts or myotubes vs. non-muscle cells (2185 and 3006, respectively) or in FSHD vs. control myoblasts or myotubes (295 and 797, respectively). Surprisingly, despite the morphologically normal differentiation of FSHD myoblasts to myotubes, most of the disease-related dysregulation was seen as dampening of normal myogenesis- specific expression changes, including in genes for muscle structure, mitochondrial function, stress responses, and signal transduction. -
Small Rnas in Early Mammalian Development: from Gametes to Gastrulation Nayoung Suh and Robert Blelloch*
REVIEW 1653 Development 138, 1653-1661 (2011) doi:10.1242/dev.056234 © 2011. Published by The Company of Biologists Ltd Small RNAs in early mammalian development: from gametes to gastrulation Nayoung Suh and Robert Blelloch* Summary Classes and biogenesis of mammalian small RNAs Small non-coding RNAs, including microRNAs (miRNAs), Three major classes of functional small non-coding RNAs have endogenous small interfering RNAs (endo-siRNAs) and Piwi- been found in mammals: microRNAs (miRNAs), endogenous interacting RNAs (piRNAs), play essential roles in mammalian small interfering RNAs (endo-siRNAs) and Piwi-interacting RNAs development. The function and timing of expression of these (piRNAs) (Babiarz and Blelloch, 2009; Kim et al., 2009; Thomson three classes of small RNAs differ greatly. piRNAs are expressed and Lin, 2009). These classes differ in their biogenesis, i.e. their and play a crucial role during male gametogenesis, whereas maturation from transcribed forms to the active form of the RNA endo-siRNAs are essential for oocyte meiosis. By contrast, (Fig. 1). miRNAs are ubiquitously expressed in somatic tissues and miRNAs can be divided into two subclasses: canonical and non- function throughout post-implantation development. canonical miRNAs. Canonical miRNAs are initially transcribed as Surprisingly, however, miRNAs are non-essential during pre- long RNAs that contain hairpins (Fig. 1A). The 60-75 nt hairpins implantation embryonic development and their function is are recognized by the RNA-binding protein Dgcr8 (DiGeorge suppressed during oocyte meiosis. Here, we review the roles of syndrome critical region 8), which directs the RNase III enzyme small non-coding RNAs during the early stages of mammalian Drosha to cleave the base of the hairpin (Denli et al., 2004; development, from gamete maturation through to Gregory et al., 2004; Han et al., 2004; Han et al., 2006; Landthaler gastrulation. -
Gene Ontology Functional Annotations and Pleiotropy
Network based analysis of genetic disease associations Sarah Gilman Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy under the Executive Committee of the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2013 Sarah Gilman All Rights Reserved ABSTRACT Network based analysis of genetic disease associations Sarah Gilman Despite extensive efforts and many promising early findings, genome-wide association studies have explained only a small fraction of the genetic factors contributing to common human diseases. There are many theories about where this “missing heritability” might lie, but increasingly the prevailing view is that common variants, the target of GWAS, are not solely responsible for susceptibility to common diseases and a substantial portion of human disease risk will be found among rare variants. Relatively new, such variants have not been subject to purifying selection, and therefore may be particularly pertinent for neuropsychiatric disorders and other diseases with greatly reduced fecundity. Recently, several researchers have made great progress towards uncovering the genetics behind autism and schizophrenia. By sequencing families, they have found hundreds of de novo variants occurring only in affected individuals, both large structural copy number variants and single nucleotide variants. Despite studying large cohorts there has been little recurrence among the genes implicated suggesting that many hundreds of genes may underlie these complex phenotypes. The question -
WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/170711 Al 13 December 2012 (13.12.2012) P O P C T (51) International Patent Classification: (72) Inventors; and G01N33/5 74 (2006.01) (75) Inventors/Applicants (for US only): PAWLOWSKI, Traci [US/US]; 2014 N Milkweed Loop, Phoenix, AZ (21) International Application Number: 85037 (US). YEATTS, Kimberly [US/US]; 109 E. Pierce PCT/US2012/041387 Street, Tempe, AZ 85281 (US). AKHAVAN, Ray (22) International Filing Date: [US/US]; 5804 Malvern Hill Ct, Haymarket, VA 201 69 7 June 2012 (07.06.2012) (US). (25) Filing Language: English (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N. MacArthur Blvd., Irving, TX 75039 (US). (26) Publication Language: English (81) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of national protection available): AE, AG, AL, AM, 61/494,196 7 June 201 1 (07.06.201 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, 61/494,355 7 June 201 1 (07.06.201 1) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 61/507,989 14 July 201 1 (14.07.201 1) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (71) Applicant (for all designated States except US): CARIS HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, LIFE SCIENCES LUXEMBOURG HOLDINGS, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, S.A.R.L [LU/LU]; Rue De Maraichers, L2124 Luxem MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, bourg, Grand-Duche De Luxembourg (LU). -
WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. -
Changes in Mirna Expression in a Model of Microcephaly Shan Parikh University of Connecticut - Storrs, [email protected]
University of Connecticut OpenCommons@UConn Honors Scholar Theses Honors Scholar Program Spring 5-9-2010 Changes in miRNA Expression in a Model of Microcephaly Shan Parikh University of Connecticut - Storrs, [email protected] Follow this and additional works at: https://opencommons.uconn.edu/srhonors_theses Part of the Cellular and Molecular Physiology Commons, and the Other Physiology Commons Recommended Citation Parikh, Shan, "Changes in miRNA Expression in a Model of Microcephaly" (2010). Honors Scholar Theses. 140. https://opencommons.uconn.edu/srhonors_theses/140 Changes in miRNA expression in a model of Microcephaly Shan Parikh Physiology and Neurobiology Abstract miRNAs function to regulate gene expression through post-transcriptional mechanisms to potentially regulate multiple aspects of physiology and development. Whole transcriptome analysis has been conducted on the citron kinase mutant rat, a mutant that shows decreases in brain growth and development. The resulting differences in RNA between mutant and wild-type controls can be used to identify genetic pathways that may be regulated differentially in normal compared to abnormal neurogenesis. The goal of this thesis was to verify, with quantitative reverse transcriptase polymerase chain reaction (qRT-PCR), changes in miRNA expression in Cit-k mutants and wild types. In addition to confirming miRNA expression changes, bio- informatics software TargetScan 5.1 was used to identify potential mRNA targets of the differentially expressed miRNAs. The miRNAs that were confirmed to change include: rno-miR- 466c, mmu-miR-493, mmu-miR-297a, hsa-miR-765, and hsa-miR-1270. The TargetScan analysis revealed 347 potential targets which have known roles in development. A subset of these potential targets include genes involved in the Wnt signaling pathway which is known to be an important regulator of stem cell development. -
Argonaute Proteins at a Glance Christine Ender and Gunter Meister
Cell Science at a Glance 1819 Argonaute proteins at a RNAs) – ncRNAs that are characteristically Biogenesis of miRNAs and siRNAs ~20-35 nucleotides long – are required for miRNAs glance the regulation of gene expression in many Generally, miRNAs are transcribed by RNA different organisms. Most small RNA species polymerase II or III to form stem-loop-structured Christine Ender1 and Gunter fall into one of the following three classes: primary miRNA transcripts (pri-miRNAs). pri- Meister1,2,* microRNAs (miRNAs), short-interfering RNAs miRNAs are processed in the nucleus by the 1 Center for Integrated Protein Science Munich (siRNAs) and Piwi-interacting RNAs (piRNAs) microprocessor complex, which contains (CIPSM), Laboratory of RNA Biology, Max-Planck- Institute of Biochemistry, Am Klopferspitz 18, 82152 (Carthew and Sontheimer, 2009). Although the RNAse III enzyme Drosha and its DiGeorge Martinsried, Germany different small RNA classes have different syndrome critical region gene 8 (DGCR8) 2University of Regensburg, Universitätsstraße 31, 93053 Regensburg, Germany bio genesis pathways and exert different cofactor. The transcripts are cleaved at the stem *Author for correspondence functions, all of them must associate with a of the hairpin to produce a stem-loop- ([email protected]) member of the Argonaute protein family for structured miRNA precursor (pre-miRNA) of Journal of Cell Science 123, 1819-1823 activity. This article and its accompanying ~70 nucleotides. After this first processing step, © 2010. Published by The Company of Biologists Ltd poster provide an overview of the different pre-miRNAs are exported into the cytoplasm by doi:10.1242/jcs.055210 classes of small RNAs and the manner in which exportin-5, where they are further processed they interact with Argonaute protein family by the RNAse III enzyme Dicer and its TRBP Although a large portion of the human genome members during small-RNA-guided gene (HIV transactivating response RNA-binding is actively transcribed into RNA, less than 2% silencing. -
(12) Patent Application Publication (10) Pub. No.: US 2009/0113561 A1 Von Melchner Et Al
US 2009.0113561A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0113561 A1 Von Melchner et al. (43) Pub. Date: Apr. 30, 2009 (54) GENE TRAP CASSETTES FOR RANDOM (30) Foreign Application Priority Data AND TARGETED CONDITIONAL GENE NACTIVATION Nov. 26, 2004 (EP) .................................. O4O281941 Apr. 18, 2005 (EP) .................................. O5103092.2 (75) Inventors: Harald Von Melchner, Publication Classification Kronberg/Taunus (DE); Frank (51) Int. Cl Schnutgen, Alzenau (DE); AOIK 67/027 (2006.01) Particia Ruiz, Berlin (DE): Silke CI2N 15/87 (2006.01) De-Zolt, Rodenbach (DE); Thomas CI2O I/68 (2006.01) Floss, Oberappersdorf (DE); Jens CI2N 5/06 (2006.01) Hansen, Kirchheim (DE) (52) U.S. Cl. .............. 800/3:536/23.1; 435/325; 800/13; 435/455: 800/25; 435/6:435/463 Correspondence Address: (57) ABSTRACT NORRIS, MCLAUGHILIN & MARCUS, PA 875 THIRDAVENUE, 18TH FLOOR A new type of gene trap cassette, which can induce condi NEW YORK, NY 10022 (US) tional mutations, relies on directional site-specific recombi nation systems, which can repair and re-induce gene trap (73) Assignee: FRANKGEN mutations when activated in Succession. After the gene trap cassettes are inserted into the genome of the target organism, BIOTECHNOLOGIE AG, mutations can be activated at a particular time and place in Kronberg (DE) Somatic cells. The gene trap cassettes also create multipur pose alleles amendable to a wide range of post-insertional (21) Appl. No.: 11/720,231 modifications. Such gene trap cassettes can be used to muta tionally inactivate all cellular genes temporally and/or spa (22) PCT Filed: Nov. -
Mutual Regulation of RNA Silencing and the IFN Response As an Antiviral Defense System in Mammalian Cells
International Journal of Molecular Sciences Review Mutual Regulation of RNA Silencing and the IFN Response as an Antiviral Defense System in Mammalian Cells Tomoko Takahashi 1,2,* and Kumiko Ui-Tei 1,3,* 1 Department of Biological Sciences, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan 2 Department of Biochemistry and Molecular Biology, Graduate School of Science and Engineering, Saitama University, Saitama 338-8570, Japan 3 Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Chiba 277-8561, Japan * Correspondence: [email protected] (T.T.); [email protected] (K.U.-T.); Tel.: +81-48-858-3404 (T.T.); +81-3-5841-3044 (K.U.-T.) Received: 23 December 2019; Accepted: 15 February 2020; Published: 17 February 2020 Abstract: RNA silencing is a posttranscriptional gene silencing mechanism directed by endogenous small non-coding RNAs called microRNAs (miRNAs). By contrast, the type-I interferon (IFN) response is an innate immune response induced by exogenous RNAs, such as viral RNAs. Endogenous and exogenous RNAs have typical structural features and are recognized accurately by specific RNA-binding proteins in each pathway. In mammalian cells, both RNA silencing and the IFN response are induced by double-stranded RNAs (dsRNAs) in the cytoplasm, but have long been considered two independent pathways. However, recent reports have shed light on crosstalk between the two pathways, which are mutually regulated by protein–protein interactions triggered by viral infection. This review provides brief overviews of RNA silencing and the IFN response and an outline of the molecular mechanism of their crosstalk and its biological implications. -
Trna-Derived Short Non-Coding RNA As Interacting Partners of Argonaute Proteins
Thomas Jefferson University Jefferson Digital Commons Computational Medicine Center Faculty Papers Computational Medicine Center 7-9-2015 tRNA-Derived Short Non-coding RNA as Interacting Partners of Argonaute Proteins. Megumi Shigematsu Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University Yohei Kirino, PhD Computational Medicine Center, Sidney Kimmel Medical College, Thomas Jefferson University Follow this and additional works at: https://jdc.jefferson.edu/tjucompmedctrfp Part of the Other Medical Specialties Commons Let us know how access to this document benefits ouy Recommended Citation Shigematsu, Megumi and Kirino, PhD, Yohei, "tRNA-Derived Short Non-coding RNA as Interacting Partners of Argonaute Proteins." (2015). Computational Medicine Center Faculty Papers. Paper 7. https://jdc.jefferson.edu/tjucompmedctrfp/7 This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Computational Medicine Center Faculty Papers by an authorized administrator of the Jefferson Digital Commons.